Nuveen buys Schroders
Nuveen has agreed an all‑cash £9.9 billion takeover of Schroders, in one of Europe’s largest ever fund management deals and ending the independence of the 222‑year‑old London firm. The transaction will create a combined group with around $2.5 trillion of assets under management. Nuveen CEO William Huffman described the deal as transformational for both firms, highlighting ambitions for further growth.
The tie‑up brings together two investors already active in life sciences real estate in Europe.
Nuveen Real Estate agreed a €35 million senior secured (green) loan to Breakthrough Properties—a joint venture between Tishman Speyer and Bellco Capital—to finance the acquisition and construction of One Helix in Amsterdam. The c. 5,155 sq m asset is 100 per cent pre‑let to Neogene Therapeutics, a clinical‑stage biotech wholly owned by AstraZeneca, within the emerging cluster around Amsterdam University Medical Center.
Schroder ImmoPLUS, a real estate investment fund managed by Schroder Investment Management (Switzerland), purchased a major single‑tenant life science property in the canton of Zurich, with a 25‑year lease, a market value of around CHF 170 million and an expected net yield of 4 per cent.
🔍 Do you need deeper insights into life sciences real estate?
In addition to our regular updates, we offer bespoke research and strategic analysis for investors and developers in the life sciences sector. Whether you’re evaluating an acquisition, tracking market trends, or need a custom report, our team can help you make informed decisions.
Get in touch to discuss how we can support your next project.